PLUVICTO

lutetium lu 177 vipivotide tetraxetan

1 min read
Updated: February 23, 2026 (Published: February 22, 2026)
James Blackmer
Simple | Detailed
Radiopharmaceutical

Quick Facts

Used For
PLUVICTO is a radioactive medicine used to treat PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that...
Common Side Effects
Feeling very tired, dry mouth, upset stomach, low red blood cells, low...
Prescription
Not Required
Generic Available
No

Indications and Usage

PLUVICTO is a radioactive medicine used to treat PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has spread to other parts of the body.

PLUVICTO is a radioactive medicine used to treat PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has spread to other parts of the body.

Dosage and Administration

The recommended dose is 200 mCi given through an IV every 6 weeks for up to 6 doses.

The recommended dose is 200 mCi given through an IV every 6 weeks for up to 6 doses.

Contraindications

Pregnancy, breastfeeding, and patients with severe kidney problems.

Pregnancy, breastfeeding, and patients with severe kidney problems.

Warnings and Precautions

This medicine can lower blood counts, harm kidneys, and expose you to radiation. Your doctor will check your blood and kidney function.

This medicine can lower blood counts, harm kidneys, and expose you to radiation. Your doctor will check your blood and kidney function.

Adverse Reactions

Feeling very tired, dry mouth, upset stomach, low red blood cells, low white blood cells, low platelets, low infection-fighting cells.

Feeling very tired, dry mouth, upset stomach, low red blood cells, low white blood cells, low platelets, low infection-fighting cells.

Drug Interactions

May interact with other medicines or treatments that affect your bone marrow.

May interact with other medicines or treatments that affect your bone marrow.

Mechanism of Action

PLUVICTO sticks to a protein called PSMA on prostate cancer cells and delivers targeted radiation using lutetium-177.

PLUVICTO sticks to a protein called PSMA on prostate cancer cells and delivers targeted radiation using lutetium-177.

Related Medications

Treats These Conditions

Scroll to Top